Abstract
Direct-acting antivirals (DAAs) have been introduced for the treatment of hepatitis C virus, and the sustained virological response rate after DAAs was reported to be over 95%. Because of the high sustained virological response rate, the risk of hepatocellular carcinoma (HCC) was expected to be reduced. However, an unexpected high risk of HCC recurrence after DAA treatment was reported, and thus the dispute about the association of DAA and HCC arose. The present article reviews the interplay between DAAs and HCC.
| Original language | English |
|---|---|
| Article number | 9 |
| Journal | Hepatoma Research |
| Volume | 6 |
| DOIs | |
| State | Published - 2020 |
Bibliographical note
Publisher Copyright:© The Author(s) 2020.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Chronic hepatitis C
- direct-acting antivirals
- hepatocellular carcinoma
Fingerprint
Dive into the research topics of 'The interplay between direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver